Jaguar Health(JAGX)

Search documents
Jaguar Health(JAGX) - 2019 Q2 - Quarterly Report
2019-08-14 20:24
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) OR Delaware 46-2956775 201 Mission Street, Suite 2375 San Francisco, California 94105 (Addr ...
Jaguar Health(JAGX) - 2019 Q1 - Quarterly Report
2019-05-21 21:23
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...
Jaguar Health(JAGX) - 2018 Q4 - Annual Report
2019-04-10 13:12
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46‑2956775 (State or other jurisd ...
Jaguar Animal Health (JAGX) Presents At Noble Capital Markets Investor Conference - Slideshow
2019-01-29 17:27
Jaguar Health, Inc. Investor Presentation January 2019 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the Company's plan to file an IND in 2H 2019 for lechlemer for the possible indication of diarrhea caused by cholera, the Company's belief that lechlemer may offer a possible Priority Review Voucher opportunity, the Company's statements regarding planned ...